Prostamax
KEDP Tetrapeptide · Prostate Bioregulator
Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.
Overview
Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.
Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Research shows reduced inflammation and swelling in prostatitis models.
Mitigates inflammation and immune cell infiltration in prostate tissue.
Decreases scarring and pathological remodeling in prostate.
Promotes deheterochromatinization in elderly cells.
Potentially reactivates genes repressed during aging process.
Normalizes age-related changes in lymphocyte function.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tetrapeptide bioregulator
- Chain length
- 4 residues
- Molecular weight
- 473 Da
- Typical dose
- 10-20mg daily
- Frequency
- Daily for 10-20 days per cycle
- Cycle length
- 10-20 days
- Storage
- Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated
Molecular data
- Type
- Tetrapeptide bioregulator
- Molecular weight
- 473 Da
- Chain length
- 4 residues
KEDPDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Research protocol | IM or SubQ | 10 mg | Daily for 10-15 days |
Interactions
Complementary male reproductive bioregulators; different tissue targets.
Often combined in comprehensive anti-aging Khavinson protocols.
Different organ targets; can be used in comprehensive bioregulator protocols.
Part of Khavinson bioregulator family; targets different tissue.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual urinary symptoms
- Prostate cancer (consult oncologist)
- Known hypersensitivity
- Pregnancy (not applicable)
FAQ
Is Prostamax safe to take if I have a family history of prostate cancer?
No. The safety flags include 'carcinogenic-risk,' and the contraindications explicitly state you should consult an oncologist if you have prostate cancer. While Prostamax targets benign prostate conditions, the carcinogenic-risk flag suggests unknown interactions with cancer development. Family history warrants professional medical consultation before use.
How does Prostamax reduce prostate swelling without hormone manipulation?
Prostamax works through epigenetic chromatin remodeling—it alters the physical structure of chromatin by increasing sister chromatid exchanges and decreasing heterochromatin. This promotes 'deheterochromatinization,' reactivating genes silenced during aging. It doesn't block hormones; it resets gene expression patterns in prostate cells.
Can Prostamax help with benign prostatic hyperplasia (BPH)?
Yes. Animal studies show Prostamax reduces prostate inflammation, swelling, and scarring—the key pathologies in BPH. However, these are preclinical results in rats. Human clinical trials are absent. If you have BPH, discuss with your urologist about whether Prostamax might complement standard treatments like alpha-blockers.
Should I get a PSA test before starting Prostamax?
Yes. The file recommends PSA testing for men over 50 before use. This is essential to establish a baseline and rule out prostate cancer before starting. Repeat PSA testing during treatment is prudent, especially given the carcinogenic-risk flag in the pharmacology section.